NCT05335044View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

June 23, 2022

Study Completion Date

July 12, 2022

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-331

QD, PO

DRUG

EX5619

QD, PO

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY